Daré Bioscience to Present at the 2020 BIO Investor Forum Digital
October 07 2020 - 08:00AM
Daré Bioscience, Inc.
(NASDAQ: DARE), a
leader in women’s health innovation, today announced that Sabrina
Martucci Johnson, President and Chief Executive Officer, will
present at the 2020 BIO Investor Forum, which will be held in a
digital format October 13-15, 2020. The company presentation will
be available on demand during the virtual event for all registered
attendees.
Event registration is available at
https://www.bio.org/events/bio-investor-forum-digital/registration-pricing.
Following the conclusion of the event, a
recording of Ms. Johnson’s presentation will be available under
“Events & Presentations" in the Investor Relations section of
the Company's website at www.darebioscience.com until October 29,
2020.
About Daré BioscienceDaré
Bioscience is a clinical-stage biopharmaceutical company committed
to the advancement of innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that expand treatment
options, improve outcomes and facilitate convenience for women,
primarily in the areas of contraception, vaginal health, sexual
health, and fertility.
Daré’s clinical-stage product portfolio includes
potential first-in-category candidates in clinical development:
Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring
whose U.S. commercial rights are under a license
agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream
formulation of sildenafil to treat female sexual arousal disorder
utilizing the active ingredient in Viagra®; DARE-BV1, a unique
hydrogel formulation of clindamycin phosphate 2% to treat bacterial
vaginosis via a single application; and DARE-HRT1, a combination
bio-identical estradiol and progesterone intravaginal ring for
hormone replacement therapy following menopause. To learn more
about Daré’s full portfolio of women’s health product candidates,
and mission to deliver differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product candidates, clinical trials and
other matters. The information Daré posts on its investor relations
website or through social media channels may be deemed to be
material information. Daré encourages investors, the media, and
others interested in the company to review the information Daré
posts on its investor relations website
(https://darebioscience.gcs-web.com/) and to follow these Twitter
accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the
list of social media channels the company may use to communicate
information will be posted on the investor relations page of Daré’s
website mentioned above.
Contact:
Investors on behalf of Daré Bioscience, Inc.:Lee Roth Burns
McClellanlroth@burnsmc.com212-213-0006
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2023 to Mar 2024